By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cellectis bioresearch and Indian contract research organization Syngene International said today they will co-develop novel genetically customized cell lines.

The collaboration between the two companies will leverage Paris-based Cellectis bioresearch's genome customization technology and Syngene's biology platform and capabilities to develop recombinant and knock-out cell lines for oncology and ADME-Tox-based drug discovery research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The New York Times editorial board weighs in on scientific research misconduct.

Jun
23
Sponsored by
PerkinElmer

This webinar will demonstrate how automated liquid handling workstations can reduce bottlenecks in library preparation for next-generation sequencing, enabling scientific advances in genomics research that were not possible five years ago.